{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:38:22Z","timestamp":1790804302050,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA186644"],"award-info":[{"award-number":["CA186644"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["N01-CM-2011-0032"],"award-info":[{"award-number":["N01-CM-2011-0032"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1136\/ijgc-2023-004491","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T08:15:21Z","timestamp":1687940121000},"page":"1208-1214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1056-5967","authenticated-orcid":false,"given":"Eduardo","family":"Gonzalez-Ochoa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Milosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Corr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Girda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Croke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeh Chen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Bowering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle","family":"Ramsahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Kunos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9955-1245","authenticated-orcid":false,"given":"Stephanie","family":"Lheureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004491_bb0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2023-004491_bb0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/AOG.0000000000003311","article-title":"Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics cervical cancer staging guidelines","volume":"134","author":"Wright","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-004491_bb0020","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","article-title":"Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma","volume":"340","author":"Keys","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004491_bb0025","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004491_bb0030","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","article-title":"Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix","volume":"18","author":"Peters","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004491_bb0035","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1200\/JCO.1999.17.5.1339","article-title":"Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study","volume":"17","author":"Whitney","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004491_bb0040","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199904153401501","article-title":"Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer","volume":"340","author":"Morris","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004491_bb0045","first-page":"S7","article-title":"Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer","volume":"95 Suppl 1","author":"Beller","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1136\/ijgc-2023-004491_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2021.01.010","article-title":"In reply to Onal et al. Long-term outcomes of cervical cancer patients treated with definitive chemoradiation following a complete metabolic response","volume":"33","author":"Lin","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1136\/ijgc-2023-004491_bb0055","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1136\/ijgc-2023-004491_bb0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6096","article-title":"ENGOT-Cx11\/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer","volume":"38","author":"Lorusso","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004491_bb0065","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ijgc-2019-001135","article-title":"Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study","volume":"30","author":"Mayadev","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004491_bb0070","series-title":"Randomized phase II trial assessing the inhibitor of programmed cell death ligand 1 (PD-L1) immune checkpoint atezolizumab in locally advanced cervical cancer","author":"Roussy","year":"2021"},{"key":"10.1136\/ijgc-2023-004491_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.1019","article-title":"880Tip randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC study","volume":"31","author":"Oaknin","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004491_bb0080","article-title":"Durvalumab, in combination with and following chemotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled CALLA trial","author":"Monk","year":"2022"},{"key":"10.1136\/ijgc-2023-004491_bb0085","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004491_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncb3452","article-title":"The control of DNA repair by the cell cycle","volume":"19","author":"Hustedt","year":"2017","journal-title":"Nat Cell Biol"},{"key":"10.1136\/ijgc-2023-004491_bb0095","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrm2351","article-title":"Regulation of DNA repair throughout the cell cycle","volume":"9","author":"Branzei","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1136\/ijgc-2023-004491_bb0100","author":"Funk JO","year":"2006"},{"key":"10.1136\/ijgc-2023-004491_bb0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1136\/ijgc-2023-004491_bb0110","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science"},{"key":"10.1136\/ijgc-2023-004491_bb0115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/nar\/gkr697","article-title":"Safeguarding genome integrity: the checkpoint kinases ATR, Chk1 and Wee1 restrain CDK activity during normal DNA replication","volume":"40","author":"S\u00f8rensen","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1136\/ijgc-2023-004491_bb0120","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0320","article-title":"Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of Wee1","volume":"2","author":"Aarts","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1136\/ijgc-2023-004491_bb0125","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","article-title":"Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes P53-deficient tumor cells to DNA-damaging agents","volume":"8","author":"Hirai","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/ijgc-2023-004491_bb0130","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4161\/cbt.9.7.11115","article-title":"MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil","volume":"9","author":"Hirai","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1136\/ijgc-2023-004491_bb0135","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1158\/1078-0432.CCR-10-2580","article-title":"MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in P53-deficient pancreatic cancer xenografts","volume":"17","author":"Rajeshkumar","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004491_bb0140","article-title":"Anti-tumor effects of Wee1 kinase inhibitor with radiotherapy in human cervical cancer","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"10.1136\/ijgc-2023-004491_bb0145","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","article-title":"Phase I study evaluating Wee1 inhibitor Azd1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors","volume":"34","author":"Leijen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004491_bb0150","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1002\/cncr.33789","article-title":"Phase 1 trial of adavosertib (Azd1775) in combination with concurrent radiation and cisplatin for intermediate\u2010risk and high\u2010risk head and neck squamous cell carcinoma","volume":"127","author":"Chera","year":"2021","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004491_bb0155","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.19.00730","article-title":"Dose escalation trial of the Wee1 inhibitor adavosertib (Azd1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer","volume":"37","author":"Cuneo","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004491_bb0160","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0360-3016(00)00771-9","article-title":"Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies","volume":"48","author":"Roeske","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2023-004491_bb0165","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2017.77.4273","article-title":"Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203","volume":"36","author":"Klopp","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004491_bb0170","doi-asserted-by":"crossref","first-page":"E2151","DOI":"10.1002\/hed.24026","article-title":"Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review","volume":"38","author":"Strojan","year":"2016","journal-title":"Head Neck"},{"key":"10.1136\/ijgc-2023-004491_bb0175","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA3","article-title":"Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone","volume":"39","author":"Mileshkin","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24016670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24016670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:29:06Z","timestamp":1753234146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24016670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1048891X24016670"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004491","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}